new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp

January 2007

You'll hear about a new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp.

It's based on evidence of an increase in death and cardiovascular events when these drugs are used to boost hemoglobin above 12 g/dL.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote